View source for Canakinumab to scale back destruction associated with heart failure and also respiratory perform in SARSCoV2 connected myocardial harm using heightened inflammation canakinumab within Covid19 heart failure injuries The 3 C study
From EECH Central
You do not have permission to edit this page, for the following reasons:
You can view and copy the source of this page.